Pancreatic neuroendocrine tumor

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

People with MEN1 syndrome inherit a high risk of developing multiple pancreatic neuroendocrine tumors. Surgery is the only curative option but causes major complications. Researchers are testing high-dose, high-precision MR-guided radiotherapy to see if it can shrink these tumors…

This trial compares two treatment approaches for pancreatic neuroendocrine tumors that have spread or cannot be removed surgically. One group receives lutetium Lu 177 dotatate, a radioactive drug that targets tumor cells, while the other receives a combination of chemotherapy dru…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …

This Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…

This study compares two approaches to prevent pancreatic leaks after Whipple surgery: giving antibiotics for a short time with a drug called octreotide versus giving antibiotics for a longer time. About 103 adults at intermediate or high risk for leaks will take part. The goal is…

This study tested whether adding capecitabine to the chemotherapy drug temozolomide helps people with advanced pancreatic neuroendocrine tumors live longer without their cancer growing. A total of 144 adults with tumors that could not be removed by surgery took part. The goal was…

This phase 2 trial tests the drug abemaciclib (Verzenio) in 20 patients with advanced gastroenteropancreatic neuroendocrine tumors that have spread, are not responding to treatment, and cannot be surgically removed. The drug works by blocking enzymes that help cancer cells grow. …

This phase II trial is testing an oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The drug aims to slow tumor growth and improve disease control. Participants take the pill twice daily, with a possible dos…

This early-phase study tests a new radioactive drug, [212Pb] VMT-α-NET, in 24 adults with advanced neuroendocrine tumors that have not responded to other treatments. The main goal is to find a safe dose for future studies, not to treat the disease. Participants receive up to two …

This study tests a drug called lurbinectedin in people with high-grade pancreatic neuroendocrine tumors (a rare, fast-growing cancer) who have already tried standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing. About 46 adults will take …

Pancreatic neuroendocrine tumors behave unpredictably: some stay slow for years while others spread quickly, and doctors lack reliable tests to tell them apart before surgery. This study examines cell-free DNA, tiny genetic fragments shed by tumors into the bloodstream, from abou…

This study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 people with metastatic neuroendocrine tumors. The goal is to see if all tumors show up on the standard scan or if some are missed, which could change treatment. Participants will get …

This registry collects information from 2000 people who have had pancreatic surgery for benign or malignant tumors. Researchers track complications and long-term results to understand what works best. The goal is to improve quality of care and support future research.

This study looks at whether checking for two proteins, ATRX and DAXX, in biopsy samples can help predict how aggressive non-functional pancreatic neuroendocrine tumors (NF-pNETs) are. Researchers will compare biopsy results with surgical tissue from 100 adults to see if the test …